− | The frequency of mutations in ''RUNX1'' mutations has been found to be between 5-18% of all Acute Myeloid Leukemia patients tested [3]. The most common chromosomal translocation is t(8;21)(q22;q22)(RUNX1-RUNX1T1) in ''de novo'' AML, at approximately 7% [2,6]. This translocation confers a favorable prognosis in AML and other neoplasms [2,5,6]. Other mutations in ''RUNX1'' include deletions, missense, splicing, frameshift, and nonsense mutations (mostly loss of function or decreased function), and occur at a frequency of approximately 10% in AML patients [6]. These mutations are mechanistically distinct from the chromosomal translocations and confer a worse prognosis [2,5,6]. | + | The frequency of mutations in ''RUNX1'' mutations has been found to be between 5-18% of all AML patients tested [3]. The most common chromosomal translocation is t(8;21)(q22;q22)(RUNX1-RUNX1T1) in ''de novo'' AML, at approximately 7% [2,6]. This translocation confers a favorable prognosis in AML and other neoplasms [2,5,6]. Other mutations in ''RUNX1'' include deletions, missense, splicing, frameshift, and nonsense mutations (mostly loss of function or decreased function), and occur at a frequency of approximately 10% in AML patients [6]. These mutations are mechanistically distinct from the chromosomal translocations and confer a worse prognosis [2,5,6]. |